The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Axi-cel proves effective as first-line treatment for high-risk lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 CAR T-cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Monjuvi improves PFS in r/r follicular lymphoma in phase III trial

Incyte announced positive topline results from the phase III inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide (Revlimid) and rituximab (Rituxan) compared to lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma.
Drugs & Targets

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

The National Comprehensive Cancer Network added Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy, to the NCCN Clinical Practice Guidelines in Oncology. Lymphir is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with CTCL.
Drugs & Targets

EC grants conditional marketing authorization for Tepkinly for r/r FL

The European Commission granted conditional marketing authorization for Tepkinly (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. Tepkinly is the only subcutaneous T-cell engaging bispecific antibody approved to treat both r/r FL and r/r diffuse large B-cell lymphoma in the EU, as well as the European Economic Area countries (Iceland, Liechtenstein, Norway) and Northern Ireland.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account